Product Description
a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. A prodrug for ACT-246475 (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26550844/)
Mechanisms of Action: P2Y12 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Idorsia
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01954615 |
AC-075-101 | P1 |
Completed |
Healthy Volunteers |
2012-03-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|